A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Multiple Myeloma Clinical Trial

Official title:

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04543305
• Other study ID #: PRT1419-01
• Status: Completed
• Phase: Phase 1
• Start date: September 28, 2020
• Est. completion date: March 21, 2022

Study information

• Verified date: November 2022
• Source: Prelude Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with relapsed/refractory hematologic malignancies. The purpose of this study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be used in subsequent development of PRT1419.

Description:

This is a multicenter, open-label, dose-escalation Phase 1 study of PRT1419, a MCL1 inhibitor, evaluating patients in two cohorts as part of a 28-day treatment cycle in adult patients with multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), high-risk myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) overlap syndrome. Cohort A will evaluate PRT1419 administered as monotherapy in patients with either AML, CMML and/or high-risk MDS or MDS/MPN overlap. Cohort B will evaluate PRT1419 administered as monotherapy in patients with NHL or MM. The study will employ a "3+3" dose escalation design. The dose may be escalated until a dose limiting toxicity is identified.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: March 21, 2022
• Est. primary completion date: March 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status of = 2

• Adequate organ function (bone marrow, hepatic, renal, cardiovascular)

• Left ventricular ejection fraction of =50%

• Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use a highly effective method of contraception during the trial

• Patients must have recovered from the effects of any prior cancer related therapy, radiotherapy or surgery (toxicity = Grade 1)

• All patients on prior investigational agents must wait at least 5 half-lives of the agent in question, or 14 days, whichever is longer before study entry

• AML patients only: Pathologically confirmed diagnosis of AML as defined by the WHO Classification and patients with targeted mutations must have been treated with appropriate therapy for their disease

• White blood cell count < 25 x 10^9/L. Hydrea or leukapheresis are permitted to meet this criterion.

• CMML patients only: intermediate-2 or high risk per CMML-specific prognostic scoring system (CPSS) or clinical/molecular CPSS (CPSS-mol) criteria. Must have failed prior therapy with a hypomethylating agent.

• MDS patients only: Intermediate, high, or very high risk by International Prognostic Scoring System-Revised [IPSS-R] criteria that is relapsed or refractory to approved therapies or MDS/MPN Overlap Syndrome (displaying both fibrosis and dysplastic features).

• NHL patients only: Histologically or cytologically confirmed NHL, including B- and T-cell lymphomas that is relapsed or refractory or intolerant to approved therapies. Must have one lesion that can be measured for response

• MM patients only: Measurable disease defined by one or more of the following: Serum M-protein = 0.5 g/dL, Urine M-protein = 200 mg/24 hours, Serum Free Light Chain (sFLC) > 10 mg/dL with normal serum FLC ratio. Presence of soft tissue plasmacytoma confirmed by imaging

• NHL and MM patients only: must have the following lab values within 14 days prior to study Day 1:

• ANC =1.0 x 10^3 µL

• Platelet count =50,000 µL

Exclusion Criteria:

• Known hypersensitivity to any of the components of PRT1419

• Female patients who are pregnant or lactating

• Mean QTcF interval of >480 msec

• History of heart failure, additional risk factors for arryhthmias or requiring concomitant medications that prolong the QT/QTc interval

• Hematopoietic stem-cell transplant < 90 days or have GVHD Grade >1 at study entry

• Uncontrolled intercurrent illnesses

• Treatment with strong inhibitors of CYP2C8 and/or P-glycoprotein for which there are no therapeutic substitutions

• Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption

• HIV positive; known active hepatitis B or C

• Prior exposure to an MCL1 inhibitor

• History of another malignancy except:

• Malignancy treated with curative intent with no known active disease for >2 years at study entry

• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease

• Adequately treated carcinoma in situ without evidence of disease

• Other concurrent low-grade malignancies (i.e chronic lymphocytic leukemia (Rai 0)) may be considered after consultation with Sponsor.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Hematologic Neoplasms
• Multiple Myeloma
• Myelodysplastic Syndromes
• Non Hodgkin Lymphoma

Intervention

Drug:
• PRT1419
PRT1419 will be administered orally

Locations

Country	Name	City	State
United States	Colorado Blood Cancer Institute	Denver	Colorado
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Florida Cancer Specialists	Lake Mary	Florida
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Florida Cancer Specialists	Sarasota	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Prelude Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To describe dose limiting toxicities (DLT) of PRT1419	Dose limiting toxicities will be evaluated through the first cycle	Baseline through Day 28
Primary	To determine the maximally tolerated dose (MTD) and/or optimal biological dose (OBD)	The MTD and/or OBD will be established for further investigation in participants with multiple myeloma, Non-Hodgkin's Lymphoma, acute myeloid leukemia and myelodysplastic syndrome	Baseline through approximately 2 years
Primary	To determine the recommended phase 2 dose (RP2D) and schedule of PRT1419	The RP2D will be established for further investigation in participants with multiple myeloma, Non-Hodgkin's Lymphoma, acute myeloid leukemia and myelodysplastic syndrome	Baseline through approximately 2 years
Secondary	To describe the adverse event profile and tolerability of PRT1419	Adverse events as characterized by type, frequency, severity, timing, seriousness and relationship to study therapy	Baseline through approximately 2 years
Secondary	To describe the pharmacokinetic profile of PRT1419	PRT1419 pharmacokinetics will be calculated including the maximum observed plasma concentration	Baseline through approximately 2 years
Secondary	To describe any anti-tumor activity of PRT1419	Anti-tumor activity of PRT1419 will be based on the measurement of objective responses	Baseline through approximately 2 years